Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Appointments in Conjunction With Theratechnologies Annual Meeting
Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies
Theratechnologies to Focus Its Commercialization Activities on the North American Territory
Theratechnologies to Present at Bloom Burton & Co. Healthcare Investor Conference 2022
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies. We currently have a Phase 1 clinical trial underway in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for NASH, a severe liver condition which affects a growing number of people around the world.
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.